Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses venetoclax and the future of treatment of multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2, which is generally highly expressed on multiple myeloma cells. According to Dr Kumar, pre-clinical studies show that venetoclax is active against myeloma cells and he further discusses the results of the Phase I trial of venetoclax as a single agent (NCT01794520) and the Phase I trial of venetoclax with bortezomib and dexamethasone (NCT01794507).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: Venetoclax and the future of treatment of multiple myeloma
